As an internationally recognized journal, Molecular Cancer is dedicated to the innovation of how basic cancer research drives advances in cancer prevention, diagnostics, and treatment. Ranked in the top 25% in the Oncology category of Journal Citation Reports, the journal receives over 70,000 article accesses a month. The journal prides itself on less than 7 days time-to-first-decision, welcoming submissions of broad interest including: target therapies; molecular and cellular biology; genomics; genetics and epigenetics; pathology and tumor immunology. Molecular Cancer is the definitive journal for researchers and clinicians in the field of molecular oncology.
Letter to the Editor